Dierckx et al. JCC 2019;13(3):389–394
In this paper, researchers investigated GlycA levels in a cohort of healthy individuals, Crohn’s disease and ulcerative colitis patients prior to and after therapeutic control of inflammation.
GlycA levels were significantly higher in patients with active IBD compared to healthy controls, and accurately reflected the mucosal recovery to a ‘healthy’ state in both CD and UC patients achieving mucosal healing. GlycA provided great potential in diagnosing low-grade inflammation in IBD; being more stable than C-reactive protein (CRP) and easier to collect than fecal calprotectin (fCal). All in all, GlycA holds promise as a viable serological biomarker for disease activity in IBD, even in patients without elevated CRP, and should therefore be tested in large prospective cohorts.